Qu Biologics Inc., a biopharmaceutical company developing Site Specific Immunomodulators (SSIs) designed to “reboot” the body’s innate immune system, announces the peer-reviewed publication of proof of principle data in chronic obstructive pulmonary disease (COPD) in the journal, Respiratory Research. The study demonstrates success with Qu Biologics’ QBKPN SSI in reducing airway inflammation in a smoke-induced lung inflammation mouse model of…
Read More
Dr. Julienne Jagdeo is a recent graduate and current postdoctoral fellow in the laboratory of Dr. Eric Jan at the University of British Columbia. Her research is focused on the identification of novel viral protease cleavage substrates during picornavirus infection. We sat down with Dr. Jagdeo to discuss her project, and its implications for future viral therapies. Why are you…
Read More
The Lynn Lab focuses on understanding the development, function and aging of insulin-producing pancreatic ß-cells with the goal of using our knowledge to be able to regenerate the functional ß-cell mass that is lost in those with diabetes. We use both human and mouse models to study ß-cells and are particularly interested understanding how transcription factors alter ß-cell function in health and disease.
Read More
Discover the Vancouver researchers who were awarded grants, awards, fellowships, and scholarships this past month! Winners include Dr. Michael Hayden (pictured), a Killam professor of Medical Genetics at the University of British Columbia, who was inducted into the Canadian Medical Hall of Fame on May 4th, 2017.
Read More
A clinical trial for a type of brain stimulation therapy is underway at Surrey Memorial Hospital, and one expert says it can help youth suffering from addiction and depression, when all other options have failed. Faranak Farzan, an assistant professor of mechatronic engineering at Simon Fraser University, says transcranial magnetic stimulation — or TMS — is much less invasive  than other methods…
Read More
New medicines are no longer one-size-fits-all. Therapies are more complex, manufactured in smaller batches and personalized for specific patient groups or even individuals. New pharmaceutical manufacturing technologies with greater flexibility, cost-effectiveness and quality assurance are needed to make those therapies. Seated at their laptops, a microbiologist and an engineer wrote a business plan to upend how injectable therapies are manufactured.…
Read More

Genetic Modifiers of Multiple Sclerosis Progression, Severity and Onset

The focus of our research is to discover pathogenic mutations leading to the onset of multiple sclerosis in multi-incident families, and the identification of genetic modifiers of disease course and severity. We envision the identification of functionally relevant genetic determinants in multiple sclerosis to define the molecular etiology of disease, provide an immediate means for accurate risk evaluation and early disease diagnosis, reveal novel targets and biomarkers for therapeutic intervention...
Read More

Spring 2017 Seed Grants Announced

We are pleased to announce the recipients of the Spring 2017 Seed Grants. These grants are designed to support novel research projects proposed by ICORD Principal Investigators and Investigators, and are made possible with the support of the Rick Hansen Foundation, ICORD and the BICP. These projects were funded in the Spring 2017 Seed Grant competition:
Read More

Imaging Technique May Reduce Cost, Timeline of Clinical Trials in MS

“Think of a multiple sclerosis lesion as the tip of the iceberg,” says Dr. Alex Rauscher. “It’s not just what’s happening inside the lesion that we need to think about – what happens in the surrounding tissue affects the brain as well.” By using advanced, highly-sensitive magnetic resonance imaging (MRI) techniques, Dr. Rauscher and his team are hoping to better…
Read More
In one of the most comprehensive studies to date, UBC researchers have identified potential adverse reactions of a commonly used multiple sclerosis drug. The study aimed to identify potential adverse events related to beta-interferon treatment for relapsing-remitting multiple sclerosis by analyzing health records of over 2,000 British Columbians with multiple sclerosis between 1995 and 2008. “Once a drug is released…
Read More